Rabeprazole is superior to ranitidine in the management of active duodenal ulcer disease: results of a double-blind, randomized North American study

• Published in: The American journal of gastroenterology Vol. 95; no. 4; pp. 936 - 942
• Main Authors: BREITER, J. R, RIFF, D, HUMPHRIES, T. J
• Format: Journal Article
• Language: English
• Published: Oxford Blackwell Publishing 01.04.2000; Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
• Subjects: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents - adverse effects; Anti-Ulcer Agents - therapeutic use; Benzimidazoles - adverse effects; Benzimidazoles - therapeutic use; Biological and medical sciences; Digestive system; Double-Blind Method; Duodenal Ulcer - drug therapy; Duodenoscopy; Female; Gastroenterology; Humans; Male; Medical sciences; Middle Aged; Omeprazole - analogs & derivatives; Pain Measurement; Pharmacology. Drug treatments; Rabeprazole; Ranitidine - adverse effects; Ranitidine - therapeutic use; Treatment Outcome; Human; Rabeprazole; Antihistaminic; Proton pump inhibitor; Chemotherapy; Gastroduodenal; Benzimidazole derivatives; Ranitidine; Digestive diseases; Intestinal disease; Ulcer; Comparative study; Gastric disease
• ISSN: 0002-9270; 1572-0241
• DOI: 10.1111/j.1572-0241.2000.01933.x

The primary purpose of this study was to compare the efficacy and tolerability of rabeprazole versus ranitidine in the treatment of patients with active duodenal ulcer disease. This multicenter, double-blind, randomized, parallel-group study enrolled 376 patients. Patients were randomly assigned to receive rabeprazole 20 mg administered once daily in the morning (q.a.m.) with matching ranitidine placebo twice daily (b.i.d.) (n = 188), or ranitidine 150 mg b.i.d. with matching rabeprazole placebo q.a.m. (n = 188). Three visits were scheduled: wk 0 (baseline; days -3 to -1), wk 2 (day 15+/-3 days), and wk 4 (day 29+/-3 days). The primary efficacy response variable was defined as complete regeneration of the mucosa at the site of all ulcers identified during the study. Secondary efficacy variables included patients' ratings of frequency and severity of ulcer pain, frequency of antacid use, and improvement of overall physical well-being. Tolerability was evaluated with analyses of adverse events, laboratory evaluations, fasting serum gastrin levels, vital signs, body weight, and electrocardiograms. Up to 4 wk of treatment with rabeprazole 20 mg q.a.m. produced significantly greater healing rates, compared to treatment with ranitidine 150 mg b.i.d. (83% vs 73%; p = 0.017). Significant differences between treatment groups were also observed for secondary efficacy indices. At wk 2, rabeprazole was more likely than ranitidine to produce complete resolution of duodenal ulcer pain (39% vs 25%; p = 0.006), improvement in duodenal ulcer nighttime pain severity (76% vs 65%; p = 0.044), and improvement in overall well-being (55% vs 41%; p = 0.009). At wk 4, the proportion of patients with normalization of overall well-being was significantly higher in the rabeprazole group than in the ranitidine group (45% vs 29%; p = 0.003). Rabeprazole was safe and well tolerated in this study. In patients with active duodenal ulcer disease, rabeprazole 20 mg q.a.m. is superior to ranitidine 150 mg b.i.d. in healing, resolving ulcer pain frequency, improving nighttime pain severity, and improving overall well-being. Rabeprazole is an effective and well-tolerated alternative treatment for patients with active duodenal ulcer disease.